98%
921
2 minutes
20
Background: Hypoglycemia is a common and serious adverse effect of diabetes treatment, especially for patients using insulin or insulin secretagogues. Guidelines recommend that these patients be assessed for interval hypoglycemic events at each clinical encounter and be provided anticipatory guidance for hypoglycemia prevention.
Objective: To determine the frequency and content of hypoglycemia communication in primary care visits.
Design: Qualitative study PARTICIPANTS: We examined 83 primary care visits from one urban health practice representing 8 clinicians and 33 patients using insulin or insulin secretagogues.
Approach: Using a directed content analysis approach, we analyzed audio-recorded primary care visits collected as part of the Achieving Blood Pressure Control Together study, a randomized trial of behavioral interventions for hypertension. The coding framework included communication about interval hypoglycemia, defined as discussion of hypoglycemic events or symptoms; the components of hypoglycemia anticipatory guidance in diabetes guidelines; and hypoglycemia unawareness. Hypoglycemia documentation in visit notes was compared to visit transcripts.
Key Results: Communication about interval hypoglycemia occurred in 24% of visits, and hypoglycemic events were reported in 16%. Despite patients voicing fear of hypoglycemia, clinicians rarely assessed hypoglycemia frequency, severity, or its impact on quality of life. Hypoglycemia anticipatory guidance was provided in 21% of visits which focused on diet and behavior change; clinicians rarely counseled on hypoglycemia treatment or avoidance of driving. Limited discussions of hypoglycemia unawareness occurred in 8% of visits. Documentation in visit notes had low sensitivity but high specificity for ascertaining interval hypoglycemia communication or hypoglycemic events, compared to visit transcripts.
Conclusions: In this high hypoglycemia risk population, communication about interval hypoglycemia and counseling for hypoglycemia prevention occurred in a minority of visits. There is a need to support clinicians to more regularly assess their patients' hypoglycemia burden and enhance counseling practices in order to optimize hypoglycemia prevention in primary care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175615 | PMC |
http://dx.doi.org/10.1007/s11606-020-06385-x | DOI Listing |
Diabetologia
September 2025
Centre Universitaire de Diabétologie et de ses Complications, AP-HP, Hôpital Lariboisière, Paris, France.
Aims/hypothesis: Severe hypoglycaemia events (SHE) remain frequent in people with type 1 diabetes despite advanced diabetes technologies. We examined whether time below range (TBR) 3.9 mmol/l (70 mg/dl; TBR70) or 3.
View Article and Find Full Text PDFMinerva Cardiol Angiol
September 2025
Department of Pharmacology, MGM Medical College and Hospital, MGM Institute of Health Sciences, Nerul, Navi Mumbai, India.
Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.
View Article and Find Full Text PDFG Ital Nefrol
August 2025
Infermiere Professionale SSD Nefrologia e Dialisi P.O. Soverato, ASP CZ.
Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Division of Pediatric Endocrinology, School of Medicine, Trakya University, Edirne, Türkiye.
Insulin tolerance tests (ITTs), glucagon tests, and low or standard-dose adrenocorticotropic hormone tests are used to evaluate the hypothalamic-pituitary-adrenal (HPA) axis. While ITT is considered the gold standard test for stimulating both the cortisol and growth hormone axis, its use in young children carries a risk of hypoglycemia, making it potentially unsafe. Recent studies indicate that L-dopa stimulates the release of adrenocorticotropic hormone and cortisol.
View Article and Find Full Text PDFJAMA Pediatr
September 2025
Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Research Theme, Children's Hospital Research Institute of Manitoba, Winnipeg, Canada.
Importance: Youth living with type 1 diabetes (T1D) are increasingly choosing automated insulin delivery (AID) systems to manage their blood glucose. Few systematic reviews meta-analyzing results from randomized clinical trials (RCTs) are available to guide decision-making.
Objective: To study the association of prolonged AID system use in an outpatient setting with measures of glucose management and quality of life in youth with T1D.